Thelansis

With the healthcare landscape shifting rapidly, teams across biopharma, consulting, med-tech, and healthcare strategy face a common bottleneck: turning scattered epidemiology data, literature, real world data and competitive signals into clear, actionable insights. Epidemiology remains the backbone of clinical development, commercial planning, medical strategy, and portfolio decision-making but in most organizations, the data is still fragmented, inconsistent, or slow to update. EpiLansis, an AI-powered epidemiology and forecasting platform by Thelansis, was designed to address the pain points. Built for scientific, commercial, and strategy teams, EpiLansis brings together real-time epidemiology data, global disease burden matrix, potential patient funnel, treatment landscapes, patient journey analytics, and disease burden insights— all in one cloud-based environment. With 350+ indications, 35+ global markets, and a robust AI-driven research engine, the platform empowers teams to...

Background: In an evolving global disease landscape, identifying the right therapy areas or indication setting for investment is a strategic move that defines a company’s growth trajectory, especially in emerging markets where potential is enormous but super fragmented. Our biopharma client, a global player aiming to expand their footprint in Asia-Pacific and Latin America, needed a reliable way to make informed, data-based decisions on where to focus its R&D and commercial resources. Thelansis partnered with the client, leveraging its disease-area gold-standard disease burden data and market intelligence to help them pinpoint high-growth therapy areas and align their R&D priorities with market needs. The client faced three key challenges: Scattered data sources with inconsistent disease and market reporting across countries. Limited visibility into disease burden trends and treatment landscape in rapidly evolving markets. Lack of an integrated framework...